Ajith P. Nair, MD
See Publications

Texas Heart Institute Positions

  • Teaching Staff, Cardiovascular Disease Fellowship
  • Associate Program Director, Advanced Heart Failure and Transplant Cardiology Fellowship

Interests

  • Congestive Heart Failure
  • Cardiac Transplantation
  • Mechanical Assist Devices
  • Pulmonary Hypertension
  • General Cardiology

Education

  • Undergraduate:

    University of Texas at Austin

  • Medical School:

    University of Texas Southwestern

  • Internship:

    Mount Sinai Hospital

  • Residency:

    Mount Sinai Hospital

  • Fellowships:

    Mount Sinai Hospital

Academic & Clinical Affiliations

Certifications

  • Internal Medicine, American Board of Internal Medicine
  • Cardiovascular Diseases, American Board of Internal Medicine
  • Advanced Heart Failure and Transplant, Cardiology American Board of Internal Medicine

Honors, Awards and Memberships

Publications

4862227 S7WF6DG3 1 alternatives-to-animal-experimentation 10 date desc Nair 2023 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22D5YPVIPK%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Patel%20et%20al.%22%2C%22parsedDate%22%3A%222023-07-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BPatel%2C%20R.%20B.%2C%20Reddy%2C%20V.%20Y.%2C%20Komtebedde%2C%20J.%20et%20al.%20%282023%29.%20Atrial%20fibrillation%20burden%20and%20atrial%20shunt%20therapy%20in%20heart%26%23xA0%3Bfailure%20with%20preserved%20ejection%20fraction.%20%26lt%3Bi%26gt%3BJACC%20Heart%20Fail%26lt%3B%5C%2Fi%26gt%3B%2C%20S2213-1779%2823%2900298%26%23x2013%3B6.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.05.024%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jchf.2023.05.024%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Atrial%20fibrillation%20burden%20and%20atrial%20shunt%20therapy%20in%20heart%5Cu00a0failure%20with%20preserved%20ejection%20fraction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ravi%20B.%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivek%20Y.%22%2C%22lastName%22%3A%22Reddy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Komtebedde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%20W.%22%2C%22lastName%22%3A%22Wegerich%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jadranka%22%2C%22lastName%22%3A%22Sekaric%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vijay%22%2C%22lastName%22%3A%22Swarup%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Antony%22%2C%22lastName%22%3A%22Walton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gabriel%22%2C%22lastName%22%3A%22Laurent%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stanley%22%2C%22lastName%22%3A%22Chetcuti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Matthias%22%2C%22lastName%22%3A%22Rademann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%22%2C%22lastName%22%3A%22Bergmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%22%2C%22lastName%22%3A%22McKenzie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heiko%22%2C%22lastName%22%3A%22Bugger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Raphael%20Romano%22%2C%22lastName%22%3A%22Bruno%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Howard%20C.%22%2C%22lastName%22%3A%22Herrmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deepak%20K.%22%2C%22lastName%22%3A%22Gupta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Samir%22%2C%22lastName%22%3A%22Kapadia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Robert%22%2C%22lastName%22%3A%22Gordon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Vanderheyden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%22%2C%22lastName%22%3A%22Noel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Steven%22%2C%22lastName%22%3A%22Bailey%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zachary%20M.%22%2C%22lastName%22%3A%22Gertz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-No%5Cu00ebl%22%2C%22lastName%22%3A%22Trochu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donald%20E.%22%2C%22lastName%22%3A%22Cutlip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20B.%22%2C%22lastName%22%3A%22Leon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20D.%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%20J.%22%2C%22lastName%22%3A%22van%20Veldhuisen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Angelo%22%2C%22lastName%22%3A%22Auricchio%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjiv%20J.%22%2C%22lastName%22%3A%22Shah%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Atrial%20fibrillation%20%28AF%29%20is%20a%20common%20comorbidity%20in%20patients%20with%20heart%20failure%20with%20preserved%20ejection%20fraction%20%28HFpEF%29%20and%20in%20heart%20failure%20with%20mildly%20reduced%20ejection%20fraction%20%28HFmrEF%29.%5CnOBJECTIVES%3A%20This%20study%20sought%20to%20describe%20AF%20burden%20and%20its%20clinical%20impact%20among%20individuals%20with%20HFpEF%20and%20HFmrEF%20who%20participated%20in%20a%20randomized%20clinical%20trial%20of%20atrial%20shunt%20therapy%20%28REDUCE%20LAP-HF%20II%20%5BA%20Study%20to%20Evaluate%20the%20Corvia%20Medical%2C%20Inc%20IASD%20System%20II%20to%20Reduce%20Elevated%20Left%20Atrial%20Pressure%20in%20Patients%20with%20Heart%5Cu00a0Failure%5D%29%20and%20to%20evaluate%20the%20effect%20of%20atrial%20shunt%20therapy%20on%20AF%20burden.%5CnMETHODS%3A%20Study%20investigators%20characterized%20AF%20burden%20among%20patients%20in%20the%20REDUCE%20LAP-HF%20II%20trial%20by%20using%20ambulatory%20cardiac%20patch%20monitoring%20at%20baseline%20%28median%20patch%20wear%20time%2C%206%5Cu00a0days%29%20and%20over%20a%2012-month%20follow-up%20%28median%20patch%20wear%20time%2C%20125%5Cu00a0days%29.%20The%20investigators%20determined%20the%20association%20of%20baseline%20AF%20burden%20with%20long-term%20clinical%20events%20and%20examined%20the%20effect%20of%20atrial%20shunt%20therapy%20on%20AF%20burden%20over%20time.%5CnRESULTS%3A%20Among%20367%20patients%20with%20cardiac%20monitoring%20data%20at%20baseline%20and%20follow-up%2C%20194%20%2853%25%29%20had%20a%20history%20of%20AF%20or%20atrial%20flutter%20%28AFL%29%2C%20and%20median%20baseline%20AF%20burden%20was%200.012%25%20%28IQR%3A%200%25-1.3%25%29.%20After%20multivariable%20adjustment%2C%20baseline%20AF%20burden%5Cu00a0%5Cu22650.012%25%20was%20significantly%20associated%20with%20heart%20failure%20%28HF%29%20events%20%28HR%3A%202.00%3B%2095%25%5Cu00a0CI%3A%201.17-3.44%3B%20P%5Cu00a0%3D%5Cu00a00.01%29%20both%20with%20and%20without%20a%20history%20of%20AF%20or%20AFL%20%28P%20for%20interaction%5Cu00a0%3D%5Cu00a00.68%29.%20Adjustment%20for%20left%20atrial%20reservoir%20strain%20attenuated%20the%20baseline%20AF%20burden-HF%20event%20association%20%28HR%3A%201.71%3B%2095%25%5Cu00a0CI%3A%200.93-3.14%3B%20P%5Cu00a0%3D%5Cu00a00.08%29.%20Of%20the%20367%20patients%2C%20141%20%2838%25%29%20had%20patch-detected%20AF%20during%20follow-up%20without%20a%20history%20of%20AF%20or%20AFL.%20Atrial%20shunt%20therapy%20did%20not%20change%20AF%20incidence%20or%20burden%20during%20follow-up.%5CnCONCLUSIONS%3A%20In%20HFpEF%20and%20HFmrEF%2C%20nearly%2040%25%20of%20patients%20have%20subclinical%20AF%20by%201%20year.%20Baseline%20AF%20burden%2C%20even%20at%20low%20levels%2C%20is%20associated%20with%20HF%20events.%20Atrial%20shunt%20therapy%20does%20not%20affect%20AF%20incidence%20or%20burden.%20%28A%5Cu00a0Study%20to%20Evaluate%20the%20Corvia%20Medical%2C%20Inc%20IASD%20System%20II%20to%20Reduce%20Elevated%20Left%20Atrial%20Pressure%20in%20Patients%20with%20Heart%5Cu00a0Failure%20%5BREDUCE%20LAP-HF%20II%5D%3B%20NCT03088033%29.%22%2C%22date%22%3A%222023-07-10%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jchf.2023.05.024%22%2C%22ISSN%22%3A%222213-1787%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22S7WF6DG3%22%2C%22LIMU9MDX%22%5D%2C%22dateModified%22%3A%222023-07-27T16%3A53%3A48Z%22%7D%7D%2C%7B%22key%22%3A%228Z3ZBAW9%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Hoeper%20et%20al.%22%2C%22parsedDate%22%3A%222023-04-20%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BHoeper%2C%20M.%20M.%2C%20Badesch%2C%20D.%20B.%2C%20Ghofrani%2C%20H.%20A.%20et%20al.%20%282023%29.%20Phase%203%20trial%20of%20sotatercept%20for%20treatment%20of%20pulmonary%20arterial%20hypertension.%20%26lt%3Bi%26gt%3BN%20Engl%20J%20Med%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B388%26lt%3B%5C%2Fi%26gt%3B%2C%201478%26%23x2013%3B1490.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJMoa2213558%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1056%5C%2FNEJMoa2213558%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Phase%203%20trial%20of%20sotatercept%20for%20treatment%20of%20pulmonary%20arterial%20hypertension%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marius%20M.%22%2C%22lastName%22%3A%22Hoeper%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20B.%22%2C%22lastName%22%3A%22Badesch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22H.%20Ardeschir%22%2C%22lastName%22%3A%22Ghofrani%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22J.%20Simon%20R.%22%2C%22lastName%22%3A%22Gibbs%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mardi%22%2C%22lastName%22%3A%22Gomberg-Maitland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vallerie%20V.%22%2C%22lastName%22%3A%22McLaughlin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ioana%20R.%22%2C%22lastName%22%3A%22Preston%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rogerio%22%2C%22lastName%22%3A%22Souza%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Aaron%20B.%22%2C%22lastName%22%3A%22Waxman%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ekkehard%22%2C%22lastName%22%3A%22Gr%5Cu00fcnig%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Grzegorz%22%2C%22lastName%22%3A%22Kope%5Cu0107%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gisela%22%2C%22lastName%22%3A%22Meyer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Karen%20M.%22%2C%22lastName%22%3A%22Olsson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stephan%22%2C%22lastName%22%3A%22Rosenkranz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yayun%22%2C%22lastName%22%3A%22Xu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%22%2C%22lastName%22%3A%22Miller%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcie%22%2C%22lastName%22%3A%22Fowler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Butler%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joerg%22%2C%22lastName%22%3A%22Koglin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Janethe%22%2C%22lastName%22%3A%22de%20Oliveira%20Pena%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marc%22%2C%22lastName%22%3A%22Humbert%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22STELLAR%20Trial%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Pulmonary%20arterial%20hypertension%20is%20a%20progressive%20disease%20involving%20proliferative%20remodeling%20of%20the%20pulmonary%20vessels.%20Despite%20therapeutic%20advances%2C%20the%20disease-associated%20morbidity%20and%20mortality%20remain%20high.%20Sotatercept%20is%20a%20fusion%20protein%20that%20traps%20activins%20and%20growth%20differentiation%20factors%20involved%20in%20pulmonary%20arterial%20hypertension.%5CnMETHODS%3A%20We%20conducted%20a%20multicenter%2C%20double-blind%2C%20phase%203%20trial%20in%20which%20adults%20with%20pulmonary%20arterial%20hypertension%20%28World%20Health%20Organization%20%5BWHO%5D%20functional%20class%20II%20or%20III%29%20who%20were%20receiving%20stable%20background%20therapy%20were%20randomly%20assigned%20in%20a%201%3A1%20ratio%20to%20receive%20subcutaneous%20sotatercept%20%28starting%20dose%2C%200.3%20mg%20per%20kilogram%20of%20body%20weight%3B%20target%20dose%2C%200.7%20mg%20per%20kilogram%29%20or%20placebo%20every%203%20weeks.%20The%20primary%20end%20point%20was%20the%20change%20from%20baseline%20at%20week%2024%20in%20the%206-minute%20walk%20distance.%20Nine%20secondary%20end%20points%2C%20tested%20hierarchically%20in%20the%20following%20order%2C%20were%20multicomponent%20improvement%2C%20change%20in%20pulmonary%20vascular%20resistance%2C%20change%20in%20N-terminal%20pro-B-type%20natriuretic%20peptide%20level%2C%20improvement%20in%20WHO%20functional%20class%2C%20time%20to%20death%20or%20clinical%20worsening%2C%20French%20risk%20score%2C%20and%20changes%20in%20the%20Pulmonary%20Arterial%20Hypertension-Symptoms%20and%20Impact%20%28PAH-SYMPACT%29%20Physical%20Impacts%2C%20Cardiopulmonary%20Symptoms%2C%20and%20Cognitive%5C%2FEmotional%20Impacts%20domain%20scores%3B%20all%20were%20assessed%20at%20week%2024%20except%20time%20to%20death%20or%20clinical%20worsening%2C%20which%20was%20assessed%20when%20the%20last%20patient%20completed%20the%20week%2024%20visit.%5CnRESULTS%3A%20A%20total%20of%20163%20patients%20were%20assigned%20to%20receive%20sotatercept%20and%20160%20to%20receive%20placebo.%20The%20median%20change%20from%20baseline%20at%20week%2024%20in%20the%206-minute%20walk%20distance%20was%2034.4%20m%20%2895%25%20confidence%20interval%20%5BCI%5D%2C%2033.0%20to%2035.5%29%20in%20the%20sotatercept%20group%20and%201.0%20m%20%2895%25%20CI%2C%20-0.3%20to%203.5%29%20in%20the%20placebo%20group.%20The%20Hodges-Lehmann%20estimate%20of%20the%20difference%20between%20the%20sotatercept%20and%20placebo%20groups%20in%20the%20change%20from%20baseline%20at%20week%2024%20in%20the%206-minute%20walk%20distance%20was%2040.8%20m%20%2895%25%20CI%2C%2027.5%20to%2054.1%3B%20P%26lt%3B0.001%29.%20The%20first%20eight%20secondary%20end%20points%20were%20significantly%20improved%20with%20sotatercept%20as%20compared%20with%20placebo%2C%20whereas%20the%20PAH-SYMPACT%20Cognitive%5C%2FEmotional%20Impacts%20domain%20score%20was%20not.%20Adverse%20events%20that%20occurred%20more%20frequently%20with%20sotatercept%20than%20with%20placebo%20included%20epistaxis%2C%20dizziness%2C%20telangiectasia%2C%20increased%20hemoglobin%20levels%2C%20thrombocytopenia%2C%20and%20increased%20blood%20pressure.%5CnCONCLUSIONS%3A%20In%20patients%20with%20pulmonary%20arterial%20hypertension%20who%20were%20receiving%20stable%20background%20therapy%2C%20sotatercept%20resulted%20in%20a%20greater%20improvement%20in%20exercise%20capacity%20%28as%20assessed%20by%20the%206-minute%20walk%20test%29%20than%20placebo.%20%28Funded%20by%20Acceleron%20Pharma%2C%20a%20subsidiary%20of%20MSD%3B%20STELLAR%20ClinicalTrials.gov%20number%2C%20NCT04576988.%29.%22%2C%22date%22%3A%222023-04-20%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1056%5C%2FNEJMoa2213558%22%2C%22ISSN%22%3A%221533-4406%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22S7WF6DG3%22%2C%225WVJH2TN%22%5D%2C%22dateModified%22%3A%222023-06-08T14%3A43%3A45Z%22%7D%7D%2C%7B%22key%22%3A%22LY937V3N%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Civitello%20and%20Nair%22%2C%22parsedDate%22%3A%222023-02-28%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BCivitello%2C%20A.%20and%20%26lt%3Bstrong%26gt%3BNair%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%20%282023%29.%20Simultaneous%20heart-kidney%20transplantation%3A%20balancing%20competing%20outcomes%20for%20transplant%20wait-listed%26%23xA0%3Bpatients.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B81%26lt%3B%5C%2Fi%26gt%3B%2C%20741%26%23x2013%3B742.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2022.12.010%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2022.12.010%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Simultaneous%20heart-kidney%20transplantation%3A%20balancing%20competing%20outcomes%20for%20transplant%20wait-listed%5Cu00a0patients%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Civitello%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%22%2C%22lastName%22%3A%22Nair%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-02-28%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2022.12.010%22%2C%22ISSN%22%3A%221558-3597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229FBUJBMU%22%2C%22S7WF6DG3%22%2C%22JD5ZU4IS%22%5D%2C%22dateModified%22%3A%222023-03-13T20%3A12%3A57Z%22%7D%7D%2C%7B%22key%22%3A%223K2NLHTM%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nair%20and%20Lamba%22%2C%22parsedDate%22%3A%222023-02-07%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BNair%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%20and%20Lamba%2C%20H.%20%282023%29.%20Left%20ventricular%20assist%20devices%20and%20renal%20ramifications.%20%26lt%3Bi%26gt%3BJ%20Am%20Heart%20Assoc%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B12%26lt%3B%5C%2Fi%26gt%3B%2C%20e028450.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.028450%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FJAHA.122.028450%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Left%20ventricular%20assist%20devices%20and%20renal%20ramifications%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harveen%22%2C%22lastName%22%3A%22Lamba%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22Feb%207%2C%202023%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FJAHA.122.028450%22%2C%22ISSN%22%3A%222047-9980%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22S7WF6DG3%22%2C%22JD5ZU4IS%22%5D%2C%22dateModified%22%3A%222023-03-14T14%3A35%3A15Z%22%7D%7D%2C%7B%22key%22%3A%22ZHVIHDZR%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nair%20et%20al.%22%2C%22parsedDate%22%3A%222023-01-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BNair%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%2C%20Xie%2C%20L.%20and%20Silva%20Enciso%2C%20J.%20E.%20%282023%29.%20Myosin%20inhibitors%3A%20the%20next%20generation.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B81%26lt%3B%5C%2Fi%26gt%3B%2C%2046%26%23x2013%3B48.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2022.10.018%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2022.10.018%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Myosin%20inhibitors%3A%20the%20next%20generation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lola%22%2C%22lastName%22%3A%22Xie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jorge%20E.%22%2C%22lastName%22%3A%22Silva%20Enciso%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%222023-01-03%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2022.10.018%22%2C%22ISSN%22%3A%221558-3597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22S7WF6DG3%22%2C%22BNSCCUCI%22%5D%2C%22dateModified%22%3A%222023-06-08T14%3A12%3A52Z%22%7D%7D%2C%7B%22key%22%3A%229SC85ZEF%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Inchaustegui%20et%20al.%22%2C%22parsedDate%22%3A%222022-10-08%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BInchaustegui%2C%20C.%20A.%2C%20Patel%2C%20A.%2C%20Lamba%2C%20H.%20K.%20et%20al.%20%282022%29.%20Impact%20of%20time%20off%20anticoagulation%20in%20patients%20with%20continuous-flow%20left%20ventricular%20assist%20devices.%20%26lt%3Bi%26gt%3BJ%20Artif%20Organs%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10047-022-01367-8%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10047-022-01367-8%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Impact%20of%20time%20off%20anticoagulation%20in%20patients%20with%20continuous-flow%20left%20ventricular%20assist%20devices%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Christian%20A.%22%2C%22lastName%22%3A%22Inchaustegui%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ashley%22%2C%22lastName%22%3A%22Patel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Harveen%20K.%22%2C%22lastName%22%3A%22Lamba%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Brown%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Justin%22%2C%22lastName%22%3A%22Arunthamakun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kevin%22%2C%22lastName%22%3A%22Ting%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Subhasis%22%2C%22lastName%22%3A%22Chatterjee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%20P.%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joggy%20K.%22%2C%22lastName%22%3A%22George%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Alexis%20E.%22%2C%22lastName%22%3A%22Shafii%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%20K.%22%2C%22lastName%22%3A%22Liao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%20B.%22%2C%22lastName%22%3A%22Civitello%22%7D%5D%2C%22abstractNote%22%3A%22Patients%20with%20left%20ventricular%20assist%20devices%20%28LVADs%29%20receive%20anticoagulation%20to%20decrease%20the%20risk%20of%20thrombosis.%20Various%20circumstances%20require%20discontinuing%20anticoagulation%20in%20LVAD%20patients%2C%20but%20the%20risks%20entailed%20are%20not%20well%20defined.%20In%20a%20retrospective%20review%20of%20LVAD%20implantation%20procedures%2C%20we%20examined%20the%20effect%20of%20time%20off%20anticoagulation%20on%20thrombosis%20and%20mortality%20rates%20after%20implantation.%20An%20international%20normalized%20ratio%5Cu2009%5Cu2264%5Cu20091.5%20was%20used%20to%20screen%20for%20patients%20taken%20off%20anticoagulation.%20Patients%20were%20divided%20into%20three%20groups%20by%20the%20cumulative%20number%20of%20days%20off%20anticoagulation%3A%20no%20discontinuation%2C%20short-term%20discontinuation%20%28%26lt%3B%5Cu200930%5Cu00a0days%29%2C%20and%20long-term%20discontinuation%20%28%5Cu2265%5Cu200930%5Cu00a0days%29.%20Rates%20of%20ischemic%20stroke%2C%20pump%20thrombosis%2C%20and%20mortality%20were%20compared%20among%20groups.%20Of%20245%20patients%20who%20underwent%20LVAD%20implantation%20during%20the%20study%2C%2070%20%2828.6%25%29%20were%20off%20anticoagulation%20during%20follow-up%3A%2037%20%2815.1%25%29%20had%20short-term%20discontinuation%20%28median%2C%2011%5Cu00a0days%29%2C%20and%2033%20%2813.5%25%29%20had%20long-term%20discontinuation%20%28median%2C%20124%5Cu00a0days%29.%20Patients%20with%20long-term%20discontinuation%20had%20a%20higher%20rate%20of%20ischemic%20stroke%20%28adjusted%20hazard%20ratio%208.5%2C%20p%5Cu2009%3D%5Cu20090.001%29%20and%20death%20%28adjusted%20hazard%20ratio%203.9%2C%20p%5Cu2009%3D%5Cu20090.001%29.%20The%20three%20groups%20did%20not%20differ%20in%20pump%20thrombosis%20rate.%20We%20conclude%20that%20after%20LVAD%20implantation%2C%20discontinuing%20anticoagulation%20for%5Cu2009%5Cu2265%5Cu200930%5Cu00a0days%20is%20independently%20associated%20with%20an%20increased%20risk%20of%20ischemic%20stroke%20and%20death.%22%2C%22date%22%3A%22Oct%2008%2C%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10047-022-01367-8%22%2C%22ISSN%22%3A%221619-0904%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%229FBUJBMU%22%2C%22S7WF6DG3%22%2C%22WS63FIXU%22%2C%22ZMAN8MMI%22%2C%22VCK5HVUS%22%2C%22C2VFJYPK%22%2C%22MDTREPAF%22%5D%2C%22dateModified%22%3A%222022-11-04T15%3A28%3A42Z%22%7D%7D%2C%7B%22key%22%3A%22PPNFW2LK%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Najjar%20et%20al.%22%2C%22parsedDate%22%3A%222022-07-29%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BNajjar%2C%20S.%20N.%2C%20Dweck%2C%20B.%20E.%2C%20%26lt%3Bstrong%26gt%3BNair%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%20et%20al.%20%282022%29.%20Relation%20of%20T%20wave%20positivity%20in%20lead%20aVR%20to%20ischemic%20etiology%20of%20cardiomyopathy.%20%26lt%3Bi%26gt%3BAm%20J%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%2C%20S0002-9149%2822%2900701%26%23x2013%3B9.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.amjcard.2022.06.043%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.amjcard.2022.06.043%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Relation%20of%20T%20wave%20positivity%20in%20lead%20aVR%20to%20ischemic%20etiology%20of%20cardiomyopathy%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20N.%22%2C%22lastName%22%3A%22Najjar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bradley%20E.%22%2C%22lastName%22%3A%22Dweck%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yochai%22%2C%22lastName%22%3A%22Birnbaum%22%7D%5D%2C%22abstractNote%22%3A%22Identifying%20ischemic%20etiology%20of%20cardiomyopathy%20carries%20prognostic%20and%20therapeutic%20significance.%20Clinical%20and%20electrocardiographic%20parameters%20can%20predict%20ischemic%20cardiomyopathy.%20Positive%20T%20wave%20polarity%20in%20lead%20aVR%20%28TPaVR%29%20has%20been%20associated%20with%20adverse%20cardiac%20events%20and%20severity%20of%20coronary%20artery%20disease.%20Medical%20records%20of%20adults%20evaluated%20in%20an%20advanced%20heart%20failure%20referral%20clinic%20for%20cardiomyopathy%20with%20systolic%20dysfunction%20%28ejection%20fraction%20%5Cu2264%2040%25%29%20were%20retrospectively%20reviewed.%20Patients%20with%20ventricular%20pacing%20were%20excluded.%20Significant%20predictors%20of%20ischemic%20cardiomyopathy%20from%20a%20univariate%20logistic%20regression%20model%20were%20entered%20simultaneously%20into%20a%20multivariate%20logistic%20regression%20model.%20A%20total%20of%20180%20patients%20met%20study%20inclusion%20criteria.%20Mean%20age%20of%20the%20population%20was%2052.5%20%5Cu00b1%2015.3%20years%20old%20and%2065%25%20were%20men.%20Ischemic%20cardiomyopathy%20was%20present%20in%2052%20patients%20%2829%25%29.%20Positive%20TPaVR%20was%20present%20in%2057%20patients%20%2832%25%29.%20Ischemic%20cardiomyopathy%20was%20more%20common%20in%20patients%20with%20positive%20TPaVR%20%2863%25%20vs%2013%25%2C%20p%20%26lt%3B%200.001%29.%20Ischemic%20cardiomyopathy%20was%20independently%20predicted%20by%20male%20gender%2C%20diabetes%2C%20hyperlipidemia%2C%20absence%20of%20family%20history%20of%20cardiomyopathy%2C%20echocardiographic%20regional%20wall%20motion%20abnormality%2C%20and%20positive%20TPaVR.%20The%20strongest%20association%20was%20with%20positive%20TPaVR%20%28odds%20ratio%2030.5%2C%2095%25%20confidence%20interval%206.47%20to%20214%3B%20p%20%26lt%3B%200.001%29.%20T%20wave%20amplitude%20of%20%2B0.025%5Cu00a0mV%20in%20lead%20aVR%20was%20the%20optimal%20cutoff%20to%20distinguish%20ischemic%20and%20nonischemic%20cardiomyopathy%20in%20receiver%20operating%20characteristic%20analysis%20%28sensitivity%2069.2%25%2C%20specificity%2083.6%25%2C%20area%20under%20curve%5Cu00a0%3D%5Cu00a00.747%2C%2095%25%20confidence%20interval%200.658%20to%200.836%29.%20In%20conclusion%2C%20positive%20TPaVR%20was%20a%20strong%20predictor%20of%20ischemic%20etiology%20of%20cardiomyopathy.%22%2C%22date%22%3A%22Jul%2029%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.amjcard.2022.06.043%22%2C%22ISSN%22%3A%221879-1913%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22K4H4V8VZ%22%2C%22S7WF6DG3%22%2C%22VTWWYEIB%22%5D%2C%22dateModified%22%3A%222022-09-02T20%3A14%3A21Z%22%7D%7D%2C%7B%22key%22%3A%22RMX9T8J3%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Nair%20and%20Deswal%22%2C%22parsedDate%22%3A%222022-07-26%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3B%26lt%3Bstrong%26gt%3BNair%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%20and%20Deswal%2C%20A.%20%282022%29.%20COVID-19-associated%20fulminant%20myocarditis%3A%20Pathophysiology-related%20phenotypic%20variance.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B80%26lt%3B%5C%2Fi%26gt%3B%2C%20313%26%23x2013%3B315.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2022.06.003%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2022.06.003%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22COVID-19-associated%20fulminant%20myocarditis%3A%20Pathophysiology-related%20phenotypic%20variance%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Anita%22%2C%22lastName%22%3A%22Deswal%22%7D%5D%2C%22abstractNote%22%3A%22%22%2C%22date%22%3A%22July%2026%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2022.06.003%22%2C%22ISSN%22%3A%221558-3597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22S7WF6DG3%22%2C%222RCWVZ4F%22%5D%2C%22dateModified%22%3A%222022-08-02T14%3A40%3A13Z%22%7D%7D%2C%7B%22key%22%3A%22QTYXGFMP%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Al%20Rifai%20et%20al.%22%2C%22parsedDate%22%3A%222022-06-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BAl%20Rifai%2C%20M.%2C%20Newby%2C%20L.%20K.%2C%20%26lt%3Bstrong%26gt%3BNair%26lt%3B%5C%2Fstrong%26gt%3B%2C%20A.%20P.%20et%20al.%20%282022%29.%20SGLT-2%20inhibitors%20for%20patients%20with%20heart%20failure%3A%20what%20have%20we%20learned%20recently%3F%20%26lt%3Bi%26gt%3BCurr%20Atheroscler%20Rep%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11883-022-01038-2%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs11883-022-01038-2%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22SGLT-2%20inhibitors%20for%20patients%20with%20heart%20failure%3A%20what%20have%20we%20learned%20recently%3F%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mahmoud%22%2C%22lastName%22%3A%22Al%20Rifai%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22L.%20Kristin%22%2C%22lastName%22%3A%22Newby%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%20P.%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arunima%22%2C%22lastName%22%3A%22Misra%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20G.%22%2C%22lastName%22%3A%22Rogers%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Savitri%22%2C%22lastName%22%3A%22Fedson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Salim%20S.%22%2C%22lastName%22%3A%22Virani%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%20OF%20REVIEW%3A%20In%20this%20review%2C%20we%20discuss%20the%20mechanisms%20of%20action%20of%20sodium-glucose%20cotransporter-2%20inhibitors%20%28SGLT-2i%29%20and%20the%20purported%20protective%20effects%20for%20mitigating%20heart%20failure%20%28HF%29-related%20outcomes.%5CnRECENT%20FINDINGS%3A%20Major%20randomized%20clinical%20trials%20have%20demonstrated%20the%20cardiovascular%20safety%20and%20efficacy%20of%20SGLT-2i%20among%20patients%20without%20known%20HF%20and%20those%20with%20established%20HF%20with%20reduced%20ejection%20fraction%20or%20preserved%20ejection%20fraction%20%28HFrEF%20and%20HFpEF%20respectively%29.%20Recent%20HF%20guidelines%20have%20incorporated%20SGLT-2i%20in%20HF%20treatment%20algorithms.%20SGLT-2i%20have%20emerged%20as%20a%20novel%20treatment%20for%20both%20prevention%20of%20HF%20and%20reduction%20of%20cardiovascular%20morbidity%20and%20mortality%20among%20patients%20with%20existing%20HFrEF%20or%20HFpEF.%22%2C%22date%22%3A%22June%2002%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs11883-022-01038-2%22%2C%22ISSN%22%3A%221534-6242%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22S7WF6DG3%22%2C%227DBQSZ99%22%2C%228PULYTSK%22%2C%22ZSY78DJL%22%5D%2C%22dateModified%22%3A%222022-07-06T19%3A09%3A51Z%22%7D%7D%2C%7B%22key%22%3A%228EKVIEDS%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Borlaug%20et%20al.%22%2C%22parsedDate%22%3A%222022-05-24%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BBorlaug%2C%20B.%20A.%2C%20Blair%2C%20J.%2C%20Bergmann%2C%20M.%20W.%20et%20al.%20%282022%29.%20Latent%20pulmonary%20vascular%20disease%20may%20alter%20the%20response%20to%20therapeutic%20atrial%20shunt%20device%20in%20heart%20failure.%20%26lt%3Bi%26gt%3BCirculation%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B145%26lt%3B%5C%2Fi%26gt%3B%2C%201592%26%23x2013%3B1604.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCULATIONAHA.122.059486%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1161%5C%2FCIRCULATIONAHA.122.059486%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Latent%20pulmonary%20vascular%20disease%20may%20alter%20the%20response%20to%20therapeutic%20atrial%20shunt%20device%20in%20heart%20failure%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Barry%20A.%22%2C%22lastName%22%3A%22Borlaug%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Blair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20W.%22%2C%22lastName%22%3A%22Bergmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heiko%22%2C%22lastName%22%3A%22Bugger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%22%2C%22lastName%22%3A%22Burkhoff%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leonhard%22%2C%22lastName%22%3A%22Bruch%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20S.%22%2C%22lastName%22%3A%22Celermajer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Brian%22%2C%22lastName%22%3A%22Claggett%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%20G.%20F.%22%2C%22lastName%22%3A%22Cleland%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donald%20E.%22%2C%22lastName%22%3A%22Cutlip%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ira%22%2C%22lastName%22%3A%22Dauber%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-Christophe%22%2C%22lastName%22%3A%22Eicher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thomas%20M.%22%2C%22lastName%22%3A%22Gorter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Finn%22%2C%22lastName%22%3A%22Gustafsson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chris%22%2C%22lastName%22%3A%22Hayward%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22van%20der%20Heyden%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Gerd%22%2C%22lastName%22%3A%22Hasenfu%5Cu00df%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20L.%22%2C%22lastName%22%3A%22Hummel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20M.%22%2C%22lastName%22%3A%22Kaye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Komtebedde%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joseph%20M.%22%2C%22lastName%22%3A%22Massaro%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jeremy%20A.%22%2C%22lastName%22%3A%22Mazurek%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%22%2C%22lastName%22%3A%22McKenzie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shamir%20R.%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20C.%22%2C%22lastName%22%3A%22Petrie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marco%20C.%22%2C%22lastName%22%3A%22Post%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ajith%22%2C%22lastName%22%3A%22Nair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andreas%22%2C%22lastName%22%3A%22Rieth%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Frank%20E.%22%2C%22lastName%22%3A%22Silvestry%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Scott%20D.%22%2C%22lastName%22%3A%22Solomon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean-No%5Cu00ebl%22%2C%22lastName%22%3A%22Trochu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dirk%20J.%22%2C%22lastName%22%3A%22Van%20Veldhuisen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ralf%22%2C%22lastName%22%3A%22Westenfeld%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Martin%20B.%22%2C%22lastName%22%3A%22Leon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanjiv%20J.%22%2C%22lastName%22%3A%22Shah%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22name%22%3A%22REDUCE%20LAP-HF-II%20Investigators%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20In%20REDUCE%20LAP-HF%20II%20%28A%20Study%20to%20Evaluate%20the%20Corvia%20Medical%2C%20Inc%20IASD%20System%20II%20to%20Reduce%20Elevated%20Left%20Atrial%20Pressure%20in%20Patients%20With%20Heart%20Failure%29%2C%20implantation%20of%20an%20atrial%20shunt%20device%20did%20not%20provide%20overall%20clinical%20benefit%20for%20patients%20with%20heart%20failure%20with%20preserved%20or%20mildly%20reduced%20ejection%20fraction.%20However%2C%20prespecified%20analyses%20identified%20differences%20in%20response%20in%20subgroups%20defined%20by%20pulmonary%20artery%20systolic%20pressure%20during%20submaximal%20exercise%2C%20right%20atrial%20volume%2C%20and%20sex.%20Shunt%20implantation%20reduces%20left%20atrial%20pressures%20but%20increases%20pulmonary%20blood%20flow%2C%20which%20may%20be%20poorly%20tolerated%20in%20patients%20with%20pulmonary%20vascular%20disease%20%28PVD%29.%20On%20the%20basis%20of%20these%20results%2C%20we%20hypothesized%20that%20patients%20with%20latent%20PVD%2C%20defined%20as%20elevated%20pulmonary%20vascular%20resistance%20during%20exercise%2C%20might%20be%20harmed%20by%20shunt%20implantation%2C%20and%20conversely%20that%20patients%20without%20PVD%20might%20benefit.%5CnMETHODS%3A%20REDUCE%20LAP-HF%20II%20enrolled%20626%20patients%20with%20heart%20failure%2C%20ejection%20fraction%20%5Cu226540%25%2C%20exercise%20pulmonary%20capillary%20wedge%20pressure%20%5Cu226525%20mm%5Cu2005Hg%2C%20and%20resting%20pulmonary%20vascular%20resistance%20%26lt%3B3.5%20Wood%20units%20who%20were%20randomized%201%3A1%20to%20atrial%20shunt%20device%20or%20sham%20control.%20The%20primary%20outcome-a%20hierarchical%20composite%20of%20cardiovascular%20death%2C%20nonfatal%20ischemic%20stroke%2C%20recurrent%20HF%20events%2C%20and%20change%20in%20health%20status-was%20analyzed%20using%20the%20win%20ratio.%20Latent%20PVD%20was%20defined%20as%20pulmonary%20vascular%20resistance%20%5Cu22651.74%20Wood%20units%20%28highest%20tertile%29%20at%20peak%20exercise%2C%20measured%20before%20randomization.%5CnRESULTS%3A%20Compared%20with%20patients%20without%20PVD%20%28n%3D382%29%2C%20those%20with%20latent%20PVD%20%28n%3D188%29%20were%20older%2C%20had%20more%20atrial%20fibrillation%20and%20right%20heart%20dysfunction%2C%20and%20were%20more%20likely%20to%20have%20elevated%20left%20atrial%20pressure%20at%20rest.%20Shunt%20treatment%20was%20associated%20with%20worse%20outcomes%20in%20patients%20with%20PVD%20%28win%20ratio%2C%200.60%20%5B95%25%20CI%2C%200.42%2C%200.86%5D%3B%20P%3D0.005%29%20and%20signal%20of%20clinical%20benefit%20in%20patients%20without%20PVD%20%28win%20ratio%2C%201.31%20%5B95%25%20CI%2C%201.02%2C%201.68%5D%3B%20P%3D0.038%29.%20Patients%20with%20larger%20right%20atrial%20volumes%20and%20men%20had%20worse%20outcomes%20with%20the%20device%20and%20both%20groups%20were%20more%20likely%20to%20have%20pacemakers%2C%20heart%20failure%20with%20mildly%20reduced%20ejection%20fraction%2C%20and%20increased%20left%20atrial%20volume.%20For%20patients%20without%20latent%20PVD%20or%20pacemaker%20%28n%3D313%3B%2050%25%20of%20randomized%20patients%29%2C%20shunt%20treatment%20resulted%20in%20more%20robust%20signal%20of%20clinical%20benefit%20%28win%20ratio%2C%201.51%20%5B95%25%20CI%2C%201.14%2C%202.00%5D%3B%20P%3D0.004%29.%5CnCONCLUSIONS%3A%20In%20patients%20with%20heart%20failure%20with%20preserved%20or%20mildly%20reduced%20ejection%20fraction%2C%20the%20presence%20of%20latent%20PVD%20uncovered%20by%20invasive%20hemodynamic%20exercise%20testing%20identifies%20patients%20who%20may%20worsen%20with%20atrial%20shunt%20therapy%2C%20whereas%20those%20without%20latent%20PVD%20may%20benefit.%22%2C%22date%22%3A%22May%2024%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1161%5C%2FCIRCULATIONAHA.122.059486%22%2C%22ISSN%22%3A%221524-4539%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22S7WF6DG3%22%2C%22V4E2TPM3%22%5D%2C%22dateModified%22%3A%222022-05-27T18%3A33%3A38Z%22%7D%7D%5D%7D
Patel, R. B., Reddy, V. Y., Komtebedde, J. et al. (2023). Atrial fibrillation burden and atrial shunt therapy in heart failure with preserved ejection fraction. JACC Heart Fail, S2213-1779(23)00298–6. https://doi.org/10.1016/j.jchf.2023.05.024.
Hoeper, M. M., Badesch, D. B., Ghofrani, H. A. et al. (2023). Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med 388, 1478–1490. https://doi.org/10.1056/NEJMoa2213558.
Civitello, A. and Nair, A. (2023). Simultaneous heart-kidney transplantation: balancing competing outcomes for transplant wait-listed patients. J Am Coll Cardiol 81, 741–742. https://doi.org/10.1016/j.jacc.2022.12.010.
Nair, A. and Lamba, H. (2023). Left ventricular assist devices and renal ramifications. J Am Heart Assoc 12, e028450. https://doi.org/10.1161/JAHA.122.028450.
Nair, A., Xie, L. and Silva Enciso, J. E. (2023). Myosin inhibitors: the next generation. J Am Coll Cardiol 81, 46–48. https://doi.org/10.1016/j.jacc.2022.10.018.
Inchaustegui, C. A., Patel, A., Lamba, H. K. et al. (2022). Impact of time off anticoagulation in patients with continuous-flow left ventricular assist devices. J Artif Organs. https://doi.org/10.1007/s10047-022-01367-8.
Najjar, S. N., Dweck, B. E., Nair, A. et al. (2022). Relation of T wave positivity in lead aVR to ischemic etiology of cardiomyopathy. Am J Cardiol, S0002-9149(22)00701–9. https://doi.org/10.1016/j.amjcard.2022.06.043.
Nair, A. and Deswal, A. (2022). COVID-19-associated fulminant myocarditis: Pathophysiology-related phenotypic variance. J Am Coll Cardiol 80, 313–315. https://doi.org/10.1016/j.jacc.2022.06.003.
Al Rifai, M., Newby, L. K., Nair, A. P. et al. (2022). SGLT-2 inhibitors for patients with heart failure: what have we learned recently? Curr Atheroscler Rep. https://doi.org/10.1007/s11883-022-01038-2.
Borlaug, B. A., Blair, J., Bergmann, M. W. et al. (2022). Latent pulmonary vascular disease may alter the response to therapeutic atrial shunt device in heart failure. Circulation 145, 1592–1604. https://doi.org/10.1161/CIRCULATIONAHA.122.059486.